IN2013CN01129A - - Google Patents

Download PDF

Info

Publication number
IN2013CN01129A
IN2013CN01129A IN1129CHN2013A IN2013CN01129A IN 2013CN01129 A IN2013CN01129 A IN 2013CN01129A IN 1129CHN2013 A IN1129CHN2013 A IN 1129CHN2013A IN 2013CN01129 A IN2013CN01129 A IN 2013CN01129A
Authority
IN
India
Prior art keywords
determining
level
colorectal cancer
diagnosing
detecting
Prior art date
Application number
Other languages
English (en)
Inventor
Leah Jane Cosgrave
Bruce Tabor
Tony W Burgess
Edouard Collins Nice
Original Assignee
Commw Scient Ind Res Org
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010903140A external-priority patent/AU2010903140A0/en
Application filed by Commw Scient Ind Res Org filed Critical Commw Scient Ind Res Org
Publication of IN2013CN01129A publication Critical patent/IN2013CN01129A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IN1129CHN2013 2010-07-14 2011-07-14 IN2013CN01129A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010903140A AU2010903140A0 (en) 2010-07-14 Diagnostic for colorectal cancer
PCT/AU2011/000895 WO2012006681A1 (fr) 2010-07-14 2011-07-14 Diagnostic en matière de cancer colorectal

Publications (1)

Publication Number Publication Date
IN2013CN01129A true IN2013CN01129A (fr) 2015-07-31

Family

ID=45468816

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1129CHN2013 IN2013CN01129A (fr) 2010-07-14 2011-07-14

Country Status (13)

Country Link
US (2) US20130345322A1 (fr)
EP (2) EP2829881B1 (fr)
JP (1) JP6061344B2 (fr)
CN (2) CN105755112B (fr)
AU (1) AU2011279555B2 (fr)
BR (1) BR112013000745B1 (fr)
DK (1) DK2829881T3 (fr)
ES (1) ES2653646T3 (fr)
IN (1) IN2013CN01129A (fr)
NO (1) NO2829881T3 (fr)
PT (1) PT2829881T (fr)
RU (1) RU2013103995A (fr)
WO (1) WO2012006681A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2829881T3 (fr) * 2010-07-14 2018-01-20
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
SMT201900108T1 (it) 2012-08-09 2019-05-10 Inst Nat Sante Rech Med Diagnosi di insufficienza cardiaca
GB201218341D0 (en) * 2012-10-12 2012-11-28 Orign Sciences Ltd Diagnostic method
SG11201608053PA (en) * 2014-03-28 2016-10-28 Applied Proteomics Inc Protein biomarker profiles for detecting colorectal tumors
LT3170005T (lt) * 2014-07-18 2019-07-10 Sanofi Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas
CN106191215B (zh) * 2015-04-29 2020-03-24 中国科学院上海生命科学研究院 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用
EP3294321B1 (fr) * 2015-05-12 2024-07-31 Superlab Far East Limited Procédés de détermination d'interféron présentant des effets inhibiteurs directs sur des tumeurs et leurs utilisations
CN105219844B (zh) * 2015-06-08 2018-12-14 华夏京都医疗投资管理有限公司 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型
CN105021828B (zh) * 2015-07-20 2017-07-28 上海交通大学医学院附属新华医院 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后
CN105567846A (zh) * 2016-02-14 2016-05-11 上海交通大学医学院附属仁济医院 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用
JP6984862B2 (ja) * 2017-03-15 2021-12-22 国立大学法人金沢大学 血中ケモカインをマーカーとして用いた大腸癌の検出
CN107164535A (zh) * 2017-07-07 2017-09-15 沈阳宁沪科技有限公司 一种无创高通量甲基化结肠癌诊断、研究和治疗方法
CN110540588B (zh) * 2018-05-28 2022-08-23 香港中文大学 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
EP3870030A4 (fr) * 2018-10-23 2022-08-03 Blackthorn Therapeutics, Inc. Systèmes et procédés de sélection, de diagnostic et de stratification de patients
CN109504778B (zh) * 2019-01-11 2021-11-09 复旦大学附属中山医院 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型
CN113785199B (zh) * 2019-03-01 2024-02-09 先进标志物探索公司 用于诊断结肠直肠癌和/或其癌前阶段的蛋白质特征
JP7032764B2 (ja) * 2019-04-03 2022-03-09 京都府公立大学法人 大腸がんの検出方法
JP7300660B2 (ja) * 2019-04-03 2023-06-30 京都府公立大学法人 大腸がんの検出方法
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
WO2021097327A1 (fr) * 2019-11-13 2021-05-20 University Of Virginia Patent Foundation Traitement d'infections par clostridium difficile
EP3835789A1 (fr) 2019-12-13 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Panel de biomarqueurs pour le diagnostic du cancer colorectal
WO2022130597A1 (fr) * 2020-12-18 2022-06-23 国立大学法人東北大学 Dispositif d'inférence, procédé d'inférence, programme d'inférence, dispositif de génération et système d'inférence
AU2021409465A1 (en) * 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
KR20240004546A (ko) * 2021-04-20 2024-01-11 비전 테크 바이오 피티와이 엘티디 결장직장암에 대한 바이오마커
EP4384830A4 (fr) * 2021-08-11 2025-09-24 Vision Tech Bio Pty Ltd Procédé de détection d'adénome
WO2023128429A1 (fr) * 2021-12-31 2023-07-06 주식회사 이노제닉스 Procédé de dépistage du cancer colorectal et de l'adénome avancé, et son application
WO2023128419A1 (fr) * 2021-12-31 2023-07-06 주식회사 이노제닉스 Procédé de dépistage du cancer colorectal et des polypes colorectaux ou des adénomes avancés et son application
CN114594259B (zh) * 2022-04-22 2022-09-13 北京易科拜德科技有限公司 一种新型的用于结直肠癌预后预测和诊断的模型及其应用
PL441319A1 (pl) * 2022-05-31 2023-12-04 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro
CN116219007A (zh) * 2022-09-15 2023-06-06 绍兴积准生物科技有限公司 检测结直肠癌的生物标志物组及其应用
CN119688988A (zh) * 2024-11-25 2025-03-25 中国医学科学院肿瘤医院 Timp1和foxp3作为诊断结直肠癌的生物标志物组合及其应用
CN121186364A (zh) * 2025-11-25 2025-12-23 长兴固容生物科技有限公司 一种用于胃癌筛查、诊断的标志物组及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Timp1を用いた検出方法
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
WO2005029091A2 (fr) * 2003-09-15 2005-03-31 Oklahoma Medical Research Foundation Methode d'utilisation de mesures de cytokines pour diagnostiquer, traiter et evaluer des maladies inflammatoires et auto-immunes
BRPI0401830A (pt) 2004-05-25 2006-01-17 Bentonit Uniao Nordeste Sa Processo de produção de pós granulados secos
EP2032989B2 (fr) 2006-06-30 2015-10-28 Merck Sharp & Dohme Corp. Biomarqueur igfbp2
US9060961B2 (en) 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
US9353415B2 (en) * 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
US20080221056A1 (en) 2007-02-12 2008-09-11 Johns Hopkins University Early Detection and Prognosis of Colon Cancers
DK2472264T3 (en) * 2007-02-27 2016-02-29 Sentoclone Internat Ab Multiplekspåvisning of tumor cells using a panel of agents which bind to extracellular markers
WO2008116178A2 (fr) * 2007-03-21 2008-09-25 Vanderbilt University Systèmes et procédés pour le diagnostic et le pronostic du cancer colorectal
CA2684024A1 (fr) * 2007-05-10 2008-11-20 F. Hoffmann-La Roche Ag Utilisation de timp-1 comme marqueur du cancer colorectal
EP2559771A3 (fr) * 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Bio-marqueurs et méthodes pour déterminer la sensibilité aux modulateurs du recepteur du facteur de croissance de l'insuline (IGF1R).
WO2009037572A2 (fr) * 2007-06-04 2009-03-26 Diagnoplex Combinaisons de bio-marqueurs du cancer colorectal
US20090017463A1 (en) * 2007-07-10 2009-01-15 Vanderbilt University Methods for predicting prostate cancer recurrence
EP2271775A4 (fr) * 2008-04-08 2011-09-07 Nuclea Biomarkers Llc Panel de biomarqueurs pour la prédiction d'un cancer colorectal récurrent
US20100111969A1 (en) * 2008-10-31 2010-05-06 Apogenix Gmbh Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors
CA2745376A1 (fr) * 2008-12-01 2010-06-10 Lifespan Extension Llc Procedes et compositions pour modifier la sante, le bien-etre et l'esperance de vie
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
CN102326080B (zh) * 2009-02-20 2015-08-05 加利福尼亚大学董事会 A+生物标志物的试验
US20110177525A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
NO2829881T3 (fr) * 2010-07-14 2018-01-20

Also Published As

Publication number Publication date
US20170205414A1 (en) 2017-07-20
AU2011279555B2 (en) 2016-10-20
BR112013000745A2 (pt) 2016-05-24
EP2593795A1 (fr) 2013-05-22
NO2829881T3 (fr) 2018-01-20
EP2829881B1 (fr) 2017-08-23
EP2593795A4 (fr) 2014-01-22
ES2653646T3 (es) 2018-02-08
EP2829881A2 (fr) 2015-01-28
CN105755112B (zh) 2019-06-07
EP2829881A3 (fr) 2015-05-13
AU2011279555A1 (en) 2013-01-31
CN103140760B (zh) 2016-01-27
RU2013103995A (ru) 2014-08-20
BR112013000745B1 (pt) 2021-02-02
PT2829881T (pt) 2017-11-29
US20130345322A1 (en) 2013-12-26
DK2829881T3 (en) 2017-12-04
CN105755112A (zh) 2016-07-13
JP2013533977A (ja) 2013-08-29
CN103140760A (zh) 2013-06-05
JP6061344B2 (ja) 2017-01-18
WO2012006681A1 (fr) 2012-01-19
US10877039B2 (en) 2020-12-29

Similar Documents

Publication Publication Date Title
IN2013CN01129A (fr)
MX357550B (es) Microarn plasmaticos para la deteccion de cancer colorrectal temprano.
WO2009037572A3 (fr) Combinaisons de bio-marqueurs du cancer colorectal
WO2012021887A3 (fr) Biomarqueurs pour la détection précoce du cancer du sein
EP3683320A3 (fr) Empreinte arnmi dans le diagnostic de cancer du poumon
MX340453B (es) Biomarcadores para cancer de pulmon.
PH12012500850A1 (en) Methods for diagnosing irritable bowel syndrome
DE602006002809D1 (de) Verfahren zur erkennung eines ovarialkarzinoms
NZ624816A (en) Ratio based biomarkers and methods of use thereof
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
EA030186B9 (ru) Способ проведения количественных анализов
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
MX2011013243A (es) Marcadores de riesgo para enfermedad cardiovascular.
WO2014140933A3 (fr) Procédé de pronostic et de traitement de métastases cancéreuses
EP4219765A3 (fr) Pronostic du cancer de la prostate à l'aide de biomarqueurs
IN2014CN01787A (fr)
EA201370063A1 (ru) Фосфолипидом рака
EP2212700B8 (fr) Procédé de détection du cancer colorectal à partir d'un échantillon de selles au moyen d'une combinaison de marqueurs associant la calprotectine et le complexe hémoglobine/haptoglobine
WO2011021041A3 (fr) Dosage pronostique de détermination de la survie
WO2013112836A3 (fr) Biomarqueurs diagnostiques et pronostiques du cancer
WO2012178188A3 (fr) Panel diagnostique moléculaire de troubles gastro-intestinaux éosinophiles
WO2013057581A8 (fr) Biomarqueurs composites pour criblage, diagnostic et pronostic non invasifs de cancer colorectal
WO2010053816A3 (fr) Biomarqueurs pour le diagnostic du cancer du sein
WO2010009074A3 (fr) Procédé de prédiction et de détection de métastases tumorales
WO2015077382A3 (fr) Test cytologique et moléculaire combiné pour la détection précoce d'adénocarcinome œsophagien